{
    "title": "112_s2236",
    "content": "The Act may be cited as the \"Advancing Breakthrough Therapies for Patients Act of 2012\" and pertains to breakthrough therapies and fast track products. The Act \"Advancing Breakthrough Therapies for Patients Act of 2012\" amends Section 506 of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of drugs designated as breakthrough therapies for serious or life-threatening diseases. The Act \"Advancing Breakthrough Therapies for Patients Act of 2012\" allows sponsors to request designation of a drug as a breakthrough therapy, which must meet specific criteria within 60 days of the request. The Act allows sponsors to request designation of a drug as a breakthrough therapy if it meets specific criteria. The Secretary will expedite the development and review of the drug, including holding meetings with the sponsor and providing timely advice. The FDA works closely with drug sponsors to efficiently gather necessary data for drug approval, involving senior managers and experienced staff in the review process, providing timely communication, and assigning a project lead for efficient review and liaison. The FDA works closely with drug sponsors to efficiently gather necessary data for drug approval, involving senior managers and experienced staff in the review process, providing timely communication, and assigning a project lead for efficient review and liaison. The FDA also emphasizes the importance of designing clinical trials to be as efficient as possible, minimizing patient enrollment, trial duration, and exploring alternatives to traditional multi-phase development approaches. The Secretary shall issue draft guidance on implementing requirements for breakthrough therapies, accelerated approval, and fast track products within 18 months of the Advancing Breakthrough Therapies for Patients Act of 2012. Final guidance must be issued within 2 years after the Act's enactment. The Secretary must issue final guidance within 2 years of the Advancing Breakthrough Therapies for Patients Act of 2012. Regulations under title 21 CFR will be amended as necessary to implement the requirements for breakthrough therapies and fast track products. Guidance and regulations will distinguish between products eligible for breakthrough therapy or fast track designation. The Secretary must issue final guidance within 2 years of the Advancing Breakthrough Therapies for Patients Act of 2012, specifying actions to expedite the development and review of breakthrough therapies. Independent review by an expert entity will assess biopharmaceutical development and regulatory review programs. The Secretary will evaluate the FDA's application of regulatory processes for biopharmaceutical development under the Advancing Breakthrough Therapies for Patients Act of 2012. A report will be submitted annually to relevant committees on the impact of these processes on innovative treatments for serious conditions. The FDA will evaluate regulatory processes for biopharmaceutical development under the Advancing Breakthrough Therapies for Patients Act of 2012. The report will include information on the number of drugs requested for breakthrough therapy designation, the number of products designated as breakthrough therapy, and details on the approval process for each breakthrough therapy. The FDA will evaluate regulatory processes for biopharmaceutical development under the Advancing Breakthrough Therapies for Patients Act of 2012. Conforming amendments are made to the Federal Food, Drug, and Cosmetic Act."
}